特寶生物(688278.SH)2019年度淨利潤升301.76%至6429.39萬元 擬10派0.25元
格隆匯3月29日丨特寶生物(688278.SH)披露2019年年度報告,實現營業總收入7.30億元,同比增長62.77%;歸屬於上市公司股東的淨利潤6429.39萬元,同比增長301.76%;歸屬於上市公司股東的扣除非經常性損益的淨利潤8644.19萬元,同比增長182.11%;基本每股收益0.18元,擬每10股派發現金股利0.25元(含税)。
公司是一家主要從事重組蛋白質及其長效修飾藥物研發、生產及銷售的創新型生物醫藥企業。公司以免疫相關細胞因子藥物為主要研發方向,致力於成為以細胞因子藥物為基礎的系統性免疫解決方案的引領者,為病毒性肝炎、惡性腫瘤等重大疾病和免疫治療領域提供更優解決方案。在未來一段時間內,公司將重點聚焦慢性乙肝臨牀治癒領域,並持續取得突破。
公司已上市產品包括生物製品國家1類新藥——聚乙二醇干擾素α-2b注射液(商品名稱:“派格賓”)、注射用重組人粒細胞巨噬細胞刺激因子(商品名稱:“特爾立”)、重組人粒細胞刺激因子注射液(商品名稱:“特爾津”)和注射用重組人白介素-11(商品名稱:“特爾康”)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.